Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

1996 • 3,649 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

ERBB receptors and cancer: the complexity of targeted inhibitors

2005 • 3,200 citations

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

2006 • 3,040 citations

Induction of apoptosis in fibroblasts by c-myc protein

1992 • 2,977 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 • 2,102 citations

EGFR and cancer prognosis

2001 • 2,068 citations

Ras, PI(3)K and mTOR signalling controls tumour cell growth

2006 • 1,934 citations

A small molecule–kinase interaction map for clinical kinase inhibitors

2005 • 1,854 citations

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 • 1,834 citations

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

2004 • 1,600 citations

A Matter of Life and Cell Death

1998 • 1,523 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

2003 • 1,445 citations

Tyrosine Kinases as Targets for Cancer Therapy

2005 • 1,365 citations

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

2006 • 1,210 citations

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 • 1,206 citations

The new World Health Organization classification of lung tumours

2001 • 1,131 citations

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 • 1,080 citations

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 • 965 citations

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 • 941 citations

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

2002 • 910 citations

Essential role for oncogenic Ras in tumour maintenance

1999 • 880 citations

Reversible Tumorigenesis by MYC in Hematopoietic Lineages

1999 • 871 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 • 824 citations

EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment

2005 • 792 citations

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 • 784 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 • 782 citations

The Akt-mTOR tango and its relevance to cancer

2005 • 778 citations

Intragenic ERBB2 kinase mutations in tumours

2004 • 753 citations

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

2006 • 720 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 • 710 citations

Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell Hybridomas

1992 • 705 citations

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 704 citations

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

1988 • 704 citations

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

2006 • 698 citations

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

2005 • 669 citations

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

2005 • 640 citations

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

2005 • 609 citations

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 • 605 citations

A loss-of-function RNA interference screen for molecular targets in cancer

2006 • 597 citations

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

2005 • 590 citations

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

2006 • 587 citations

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

2001 • 582 citations

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

2006 • 579 citations

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

2006 • 568 citations

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

2005 • 556 citations

Requirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras

1997 • 547 citations

High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

2004 • 544 citations

Mutational Activation of the K-rasOncogene

1987 • 542 citations

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

2001 • 534 citations

Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis

2003 • 531 citations

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

2001 • 516 citations

Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors

2005 • 511 citations

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

2005 • 508 citations

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

2002 • 508 citations

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

2006 • 507 citations

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

2005 • 492 citations

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

2005 • 490 citations

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

1993 • 482 citations

Cancer revoked: oncogenes as therapeutic targets

2003 • 479 citations

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

2006 • 466 citations

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

2003 • 457 citations

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

2006 • 457 citations

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

2001 • 443 citations

Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

2006 • 439 citations

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

2006 • 431 citations

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

2006 • 428 citations

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1998 • 414 citations

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

2005 • 403 citations

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

2002 • 396 citations

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

2006 • 376 citations

Gefitinib — a novel targeted approach to treating cancer

2004 • 371 citations

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

2004 • 366 citations

IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients

2005 • 365 citations

Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results

2001 • 359 citations

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

2004 • 341 citations

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

2005 • 338 citations

Strategies to overcome resistance to targeted protein kinase inhibitors

2004 • 332 citations

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

2003 • 326 citations

Epidermal growth factor receptors in non-small cell lung cancer

1987 • 326 citations

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

2005 • 315 citations

AEE788

2004 • 315 citations

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

2005 • 315 citations

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

2002 • 308 citations

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

2004 • 307 citations

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

2003 • 284 citations

Regulation of cell death by the Abl tyrosine kinase

2000 • 278 citations

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

2000 • 268 citations

An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor

2005 • 266 citations

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

2000 • 261 citations

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

2000 • 258 citations

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

2005 • 257 citations

Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins

2005 • 256 citations

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

2002 • 253 citations

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

2006 • 252 citations

ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

1991 • 249 citations

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

2005 • 247 citations

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

2006 • 242 citations

Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

2005 • 236 citations

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

2005 • 233 citations

A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

2006 • 233 citations

Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)

2005 • 228 citations

CCI‐779 in metastatic melanoma

2005 • 227 citations

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

2005 • 206 citations

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

2001 • 194 citations

Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib

2007 • 191 citations

Gefitinib reverses breast cancer resistance protein–mediated drug resistance

2004 • 190 citations

Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression

2005 • 186 citations

Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90

2006 • 184 citations

Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

2005 • 177 citations

Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

2005 • 175 citations

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

2005 • 172 citations

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

2006 • 170 citations

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

2005 • 161 citations

Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

2006 • 159 citations

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer

2004 • 156 citations

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

2005 • 149 citations

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

2005 • 147 citations

Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers

1998 • 143 citations

K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos

1993 • 140 citations

Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors

2004 • 137 citations

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272

2006 • 134 citations

Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2.

1995 • 133 citations

Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

2005 • 132 citations

Clinicopathologic Significance of the Mutations of theEpidermal Growth Factor ReceptorGene in Patients with Non–Small Cell Lung Cancer

2005 • 131 citations

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

2005 • 120 citations

Epidermal growth factor receptor expression in human lung cancer cell lines

1989 • 120 citations

Where next for gefitinib in patients with lung cancer?

2006 • 119 citations

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors

2005 • 116 citations

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

1999 • 108 citations

Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases

1997 • 105 citations

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

2002 • 103 citations

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

2005 • 103 citations

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas

2005 • 98 citations

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

2006 • 97 citations

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

2005 • 96 citations

Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells

2005 • 95 citations

Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein

2005 • 95 citations

Therapeutic potential of target of rapamycin inhibitors

2004 • 84 citations

Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer Patients

2006 • 82 citations

Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors

2006 • 81 citations

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

2005 • 79 citations

Regulation of both apoptosis and cell survival by the v-Src oncoprotein

2000 • 74 citations

Expression of adenovirus E1B mutant phenotypes is dependent on the host cell and on synthesis of E1A proteins

1987 • 74 citations

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

2005 • 72 citations

Chromosome abnormalities in human non-small cell lung cancer.

1992 • 70 citations

A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma

2006 • 67 citations

Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.

1992 • 63 citations

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

2004 • 60 citations

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer

2006 • 60 citations

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

2006 • 58 citations

v-Src Generates a p53-Independent Apoptotic Signal

2000 • 51 citations

Autocrine growth stimulation by transforming growth factor-α in human non-small cell lung cancer

1992 • 46 citations

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

2006 • 43 citations

Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer

2005 • 41 citations

Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition

2006 • 40 citations

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

2006 • 40 citations

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

2005 • 38 citations

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

2006 • 30 citations

Phase II Data with ZD6474, a Small-Molecule Kinase Inhibitor of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor, in Previously Treated Advanced Non–Small-Cell Lung Cancer

2005 • 23 citations

The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line

2006 • 14 citations

Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class

2005 • 13 citations

Mutated kinases as targets for cancer drugs

2005 • 7 citations